Drug Profile
Pembrolizumab biosimilar - Formycon
Alternative Names: FYB-206Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Formycon
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies; Tumour-agnostic therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Unspecified